Raf Kinase Inhibitor Protein Preferentially Promotes Tlr3-Triggered Signaling And Inflammation

Rongrong Lai,Meidi Gu, Wei Jiang,Wenlong Lin,Penglei Xu, Zhiyong Liu,He Huang, Huazhang An,Xiaojian Wang

JOURNAL OF IMMUNOLOGY(2017)

引用 19|浏览22
暂无评分
摘要
Raf kinase inhibitor protein (RKIP) protects against host immunological responses in nematodes and Drosophila. Whether RKIP functions in innate immune responses in mammals remains unknown. In this article, we report that RKIP preferentially regulates the TLR3-mediated immune response in macrophages. RKIP deficiency or silencing significantly decreases polyinosinic: polycytidylic acid [Poly(I:C)]-induced IFN-beta, IL-6, and TNF-alpha production without affecting the counterpart induced by LPS or CpG. Compared with their wild-type counterparts, RKIP-deficient mice produce less IFN-beta, IL-6, and TNF-alpha in serum and display decreased lethality upon peritoneal Poly(I:C) plus D-galactosamine injection. Mechanistically, RKIP interacts with TBK1 and promotes the Poly(I:C)-induced TANK-binding kinase 1/IRF3 activation. Simultaneously, RKIP enhances the Poly(I:C)-induced interaction between TGF-beta-activated kinase 1 and MAPK kinase 3 (MKK3), thus promoting MKK3/6 and p38 activation. We further demonstrated that Poly(I:C) treatment, but not LPS treatment, induces RKIP phosphorylation at S109. This action is required for RKIP to promote TANK-binding kinase 1 activation, as well as the interaction between TGF-beta-activated kinase 1 and MKK3, which lead to activation of the downstream IRF3 and p38, respectively. Therefore, RKIP acts as a positive-feedback regulator of the TLR3-induced inflammatory response and may be a potential therapeutic target for inflammatory disease.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要